Celltrion completes record 1.78 trillion won share buyback, retiring 9.11 million shares representing 4% of total outstanding stock, boosting per-share value for investors as company shifts employee stock option strategy to new share issuance model
#YonhapInfomax #Celltrion #ShareBuyback #TreasuryStock #StockRetirement #EmployeeStockOptions #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=115375Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=114387
Celltrion Eyes Windfall for Zymfentra, Biosimilars from US CMS Policy Overhaul
Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share
#Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=114173
Celltrion's Truxima Achieves No. 1 Market Share in US
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
Celltrion announces biosimilars exempt from US drug tariffs, expects increased demand and plans 75,000-liter capacity expansion at New Jersey facility as Trump administration's pharmaceutical policy drives domestic production requirements for both finished products and active ingredients.
#YonhapInfomax #Celltrion #Biosimilars #USDrugTariffs #BranchburgFacility #ProductionCapacity #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=113863
Celltrion Says US Drug Tariff Impact Eliminated, Local Demand Expected to Rise
Celltrion announces biosimilars exempt from US drug tariffs, expects increased demand and plans 75,000-liter capacity expansion at New Jersey facility as Trump administration's pharmaceutical policy drives domestic production requirements for both finished products and active ingredients.
Celltrion Executes Record 1.7 Trillion Won Share Buyback
Celltrion executes record-breaking 1.7 trillion won treasury share cancellation representing 4% of outstanding shares, with remaining shares earmarked for strategic M&A and growth investments
Celltrion reports fatal fall of subcontractor worker during wastewater pipe work at Incheon Plant 2, vows comprehensive safety review and full investigation cooperation as company confirms preliminary safety procedures were completed before incident
#YonhapInfomax #Celltrion #WorkplaceSafety #FatalAccident #SongdoPlant #SubcontractorWorker #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=111370
Celltrion Worker Dies in Fall During Wastewater Pipe Work at Plant 2
Celltrion reports fatal fall of subcontractor worker during wastewater pipe work at Incheon Plant 2, vows comprehensive safety review and full investigation cooperation as company confirms preliminary safety procedures were completed before incident
Celltrion's Zymfentra prescriptions in the US reached record highs in January 2026, surging 213% year-on-year, with shipments to distributors increasing 3.5-fold, driven by the company's comprehensive 3P marketing strategy targeting providers, payers, and patients across multiple channels.
#YonhapInfomax #Celltrion #Zymfentra #Infliximab #PrescriptionGrowth #USPharmaceuticalMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=110507Celltrion secures CMO contract worth up to 375.4 billion won with undisclosed global pharma company, pushing Q1 cumulative orders past 1 trillion won following earlier Eli Lilly deal, as CDMO partnership inquiries surge
#YonhapInfomax #Celltrion #CMO #BiopharmaceuticalAPI #EliLilly #CDMO #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=110249
Celltrion Signs Drug Supply Deal Worth Up to 375.4 Billion Won with Global Pharma
Celltrion secures CMO contract worth up to 375.4 billion won with undisclosed global pharma company, pushing Q1 cumulative orders past 1 trillion won following earlier Eli Lilly deal, as CDMO partnership inquiries surge
Celltrion Says US Tariff Issue Will Not Disrupt Business Operations in Any Scenario
Celltrion Co. has implemented measures to ensure its US business remains unaffected by any tariff policy changes, leveraging local production and inventory to maintain stable operations.
LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
#YonhapInfomax #LGElectronics #SPGlobal #ESG #Celltrion #SustainabilityYearbook2026 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=106019
LG Electronics Ranks in S&P ESG Top 1% for Third Consecutive Year—Only Two Korean Firms Make the List Alongside Celltrion
LG Electronics and Celltrion are the only South Korean firms to rank in S&P Global's ESG Top 1% for 2026, highlighting LG's sustained global leadership in sustainability for three consecutive years.
Yonhap Infomax News